Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism.
Saved in:
| Title: | Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. |
|---|---|
| Authors: | Louveau B; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France.; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France., Resche-Rigon M; Department of Biostatistics, Saint Louis Hospital APHP, Paris, France.; Université de Paris, INSERM U1153, Saint Louis Hospital APHP, Paris, France., Lesimple T; Oncodermatology Unit, Eugene Marquis Center, CHU CLCC, Rennes, France., Da Meda L; Department of Dermatology, Saint Louis Hospital APHP, Paris, France.; Centre d'Investigation Clinique (CIC 1427), Saint Louis Hospital APHP, Paris, France., Pracht M; Oncodermatology Unit, Eugene Marquis Center, CHU CLCC, Rennes, France., Baroudjian B; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France.; Department of Dermatology, Saint Louis Hospital APHP, Paris, France., Delyon J; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France.; Department of Dermatology, Saint Louis Hospital APHP, Paris, France., Amini-Adle M; CHU Lyon, Lyon, France., Dutriaux C; INSERM U1035, Université de Bordeaux, Bordeaux, France., Reger de Moura C; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France., Sadoux A; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France., Jouenne F; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France.; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France., Ghrieb Z; Centre d'Investigation Clinique (CIC 1427), Saint Louis Hospital APHP, Paris, France., Vilquin P; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France.; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France., Bouton D; DRCI, APHP, Paris, France., Tibi A; AGEPS, APHP, Paris, France., Huguet S; Institut Curie, Saint Cloud, France., Rezai K; Institut Curie, Saint Cloud, France., Battistella M; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France.; Department of Pathology, APHP Saint Louis Hospital, Paris, France., Mourah S; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France.; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France., Lebbe C; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France. celeste.lebbe@aphp.fr.; Department of Dermatology, Saint Louis Hospital APHP, Paris, France. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jul 15; Vol. 27 (14), pp. 3876-3883. Date of Electronic Publication: 2021 May 04. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
